Aimei Health Technology Co Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Aimei Health Technology Co Ltd (AFJK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Aimei Health Technology Co Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Aimei Health Technology Co Ltd | - | - | - | Yes |
| Competitors combined (2) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AFJK Stock Performance relative to its Competitors
Aimei Health Technology Co Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Aimei Health Technology Co Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Aimei Health Technology Co Ltd | - | - |
| Equity Residential | 24,437.67 | 3,030.82 |
| Strategic Acquisitions Inc | 18.34 | 0.08 |
| SUBTOTAL | 24,456.01 | 3,030.90 |
Sources: Aimei Health Technology Co Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Aimei Health Technology Co Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Aimei Health Technology Co Ltd's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Strategic Acquisitions Inc | Named by the company | 85% |
| Equity Residential | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Aimei Health Technology Co Ltd's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Aimei Health Technology Co Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Aimei Health Technology Co Ltd | - | - | - |
| Equity Residential | 24,438 | 1,894,260 | 562,004 |
| Strategic Acquisitions Inc | 18 | 42,456 | -37,956 |
| PEERS TOTAL | 24,456 | 1,891,948 | 561,255 |
Aimei Health Technology Co Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 183 companies in Aimei Health Technology Co Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Aimei Health Technology Co Ltd ranks #0 of 183 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 118, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Dutch Oven Gold Group Inc | 1,683 | 5.46 % |
| 2 | Jaws Mustang Acquisition Corporation | 940 | 3.05 % |
| 3 | Mntn Inc | 828 | 2.69 % |
| 4 | Constellation Acquisition Corp I | 677 | 2.20 % |
| 5 | Drugs Made In America Acquisition Ii Corp | 1,234 | 5.2% |
| 6 | Cantor Equity Partners Iv Inc | 1,234 | 5.2% |
| 7 | Sound Point Acquisition Corp I Ltd | 1,234 | 5.2% |
| 8 | American Exceptionalism Acquisition Corp A | 1,234 | 5.2% |
| 9 | Gores Holdings X Inc | 1,234 | 5.2% |
| 10 | Aldel Financial Ii inc | 1,234 | 5.2% |
| 0 | Aimei Health Technology Co Ltd | 76 | 0.00 % |
Market cap and industry share for the rest of Aimei Health Technology Co Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-25.
Aimei Health Technology Co Ltd's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue Growth | - | - | - |
| Operating Margin | - | - | - |
| Return on Invested Capital | - | - | -2.72 % |
| P/E | - | 36.2x | 187.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Aimei Health Technology Co Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 118 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Aimei Health Technology Co Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Aimei Health Technology Co Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Aimei Health Technology Co Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- Industry revenue growing at a healthy 27.5% median pace.
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-9.4% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Aimei Health Technology Co Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Aimei Health Technology Co Ltd | 0.00 | 0.01 | - |
| Equity Residential | 0.08 | 0.08 | 0.42 |
| Strategic Acquisitions Inc | 5.55 | 7.82 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Aimei Health Technology Co Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Aimei Health Technology Co Ltd | Q2 2026 | - | - |
| Equity Residential | Q2 2026 | -10.7 % | -40.8 % |
| Strategic Acquisitions Inc | Q2 2026 | - | - |
| PEERS TOTAL | -10.7 % | -40.9 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Aimei Health Technology Co Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Aimei Health Technology Co Ltd | Q2 2026 | - | - |
| Equity Residential | Q2 2026 | +4.8 % | -80.8 % |
| Strategic Acquisitions Inc | Q2 2026 | - | - |
Aimei Health Technology Co Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Aimei Health Technology Co Ltd | 2.00% | 2.39% | - |
| Equity Residential | 4.35% | 3.91% | 8.16% |
| Strategic Acquisitions Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Aimei Health Technology Co Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Aimei Health Technology Co Ltd | 63.97 | - |
| Equity Residential | 27.68 | 8.06 |
| Strategic Acquisitions Inc | - | 215.96 |
| PEERS AVERAGE | 27.19 | 8.07 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.